Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel. Show more
Location: Building 7, Tel Aviv, 6158002, Israel | Website: https://www.chemomab.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
15.68M
52 Wk Range
$2.99 - $9.84
Previous Close
$3.02
Open
$3.01
Volume
76,250
Day Range
$3.00 - $3.10
Enterprise Value
6.312M
Cash
9.365M
Avg Qtr Burn
-3.585M
Insider Ownership
16.73%
Institutional Own.
25.92%
Qtr Updated
06/30/25
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Nebokitug Details Primary Sclerosing Cholangitis | Phase 2 Update |